ESCRS - Next-generation monofocal IOL

Next-generation monofocal IOL

Johnson & Johnson Vision has announced the launch of its TECNIS Eyhance IOL in Europe

Next-generation monofocal IOL
Colin Kerr
Colin Kerr
Published: Friday, March 1, 2019
Johnson & Johnson Vision has announced the launch of its TECNIS Eyhance IOL for the treatment of cataracts in Europe. “This next-generation monofocal intraocular lens allows patients to experience high-quality vision at both intermediate and far distances. This is an important first for the monofocal IOL category, as most lenses in this category only correct vision to help patients with cataracts see things at a distance, and thus do not improve intermediate vision required for many daily tasks,” said a company spokeswoman. “We are proud to deliver another meaningful solution for patients with cataracts,” said Tom Frinzi, Worldwide President, Surgical, Johnson & Johnson Vision. https://www.jjvision.com/
Tags: tecnis
Latest Articles
Diamonds in the Rough

The push for inclusivity in ophthalmology.

Read more...

Making Female Leadership More than a Moment

A remarkable global confluence of women in key positions.

Read more...

ESCRS Talks Technology at AAO

Europe adopts technological advances, US still waiting for lenses and lasers.

Read more...

Sorting Out Simultaneous Vision IOLs

The ESCRS Eye Journal Club discuss a new landmark paper on IOL classification and the need for harmonisation of terminology for presbyopic IOLs.

Read more...

Big Advantages to Small-Aperture IOLs

Small-aperture IOLs offer superior image quality with increased range of focus.

Read more...

Prioritising Self-Care

Benefits of maintaining physical, emotional, and mental health extend beyond the personal sphere.

Read more...

Valuing Clinical Trial Design

How inclusivity and diversity can enhance scientific accuracy in research.

Read more...

Knowing Iris Repair: Using Iridodiathermy in Iris Surgery

Prepare for decentred pupils and uneven irides in multiple situations.

Read more...

Neuroprotectant Treatment for MacTel Type 2

Intravitreal implant releasing ciliary neurotrophic factor found safe and effective in pivotal trials.

Read more...

Supplement: Maximizing Visual Quality in Refractive Surgery Through Enhanced Precision and Safety

Read more...